Armata Pharma gets USD 3.7 million more in US Department of War funding for AP-SA02 Phase 3 program

Bitget2026/09/23 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Armata received USD 3.7 million in additional non-dilutive funding from the U.S. Department of War for AP-SA02 Phase 3 development.
Total Department of War support for the AP-SA02 program rises to about USD 32.4 million.
Funds support Phase 3 work in complicated Staphylococcus aureus bacteremia, with AP-SA02 positioned as an adjunctive therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609230700PR_NEWS_USPR_____LA54741) on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Armata Pharma gets USD 3.7 million more in US Department of War funding for AP-SA02 Phase 3 program

You may also like

Crypto prices